In a filing, BioXcel Therapeutics Inc revealed its Chief Commercial Officer Wiley Matthew T. unloaded Company’s shares for reported $3450.0 on Oct 03 ’24. In the deal valued at $0.55 per share,6,272 shares were sold. As a result of this transaction, Wiley Matthew T. now holds 19,011 shares worth roughly $9695.61.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Rodriguez Javier sold 6,863 shares, generating $3,775 in total proceeds. Upon selling the shares at $0.55, the insider now owns 23,770 shares.
Before that, Yocca Frank sold 7,175 shares. BioXcel Therapeutics Inc shares valued at $3,946 were divested by the Chief Scientific Officer at a price of $0.55 per share. As a result of the transaction, Yocca Frank now holds 28,278 shares, worth roughly $14421.78.
UBS downgraded its BioXcel Therapeutics Inc [BTAI] rating to a Neutral from a a Buy in a research note published on February 21, 2024; the price target was decreased to $4 from $9. A number of analysts have revised their coverage, including Mizuho’s analysts, who decreased its forecast for the stock in mid August from “a Buy” to “a Neutral”. Guggenheim also remained covering BTAI and has decreased its forecast on July 17, 2023 with a “Neutral” recommendation from previously “Buy” rating. Jefferies revised its rating on March 10, 2023. It rated BTAI as “a Hold” which previously was an “a Buy”.
Price Performance Review of BTAI
On Friday, BioXcel Therapeutics Inc [NASDAQ:BTAI] saw its stock fall -10.80% to $0.51. Over the last five days, the stock has lost -10.43%. BioXcel Therapeutics Inc shares have fallen nearly -82.75% since the year began. Nevertheless, the stocks have fallen -86.71% over the past one year. While a 52-week high of $4.17 was reached on 02/06/24, a 52-week low of $0.50 was recorded on 11/22/24. SMA at 50 days reached $0.5995, while 200 days put it at $1.5465.
Levels Of Support And Resistance For BTAI Stock
The 24-hour chart illustrates a support level at 0.4821, which if violated will result in even more drops to 0.4553. On the upside, there is a resistance level at 0.5437. A further resistance level may holdings at 0.5785. The Relative Strength Index (RSI) on the 14-day chart is 38.56, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0655, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 92.96%. Stochastics %K at 22.68% indicates the stock is a holding.
How much short interest is there in BioXcel Therapeutics Inc?
A steep rise in short interest was recorded in BioXcel Therapeutics Inc stocks on 2024-10-31, dropping by -0.17 million shares to a total of 0.35 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 0.52 million shares. There was a decline of -48.78%, which implies that there is a negative sentiment for the stock.
